NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,196.75 +433.72 (+2.44%) CRUDE OIL
79.48 +0.48 (+0.61%) GOLD FUTURES
2,326.10 +15.10 (+0.65%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
46,002.23 -1,629.36 (-3.42%)
Sandoz Group AG (0SAN.L)
| Previous close | 31.13 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | N/A x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 250,699 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmedMathai Mammen, Graeme Pitkethly and Michael Rechsteiner elected as new Board membersDividend of CHF 0.45 per registered dividend-paying share approved, representing 24% of core net income Basel, April 30, 2024 – Sandoz (SIX: SDZ; OTCQX: SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its
Globe NewswireSandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on May 31, 2025 or earlier under certain circumstancesJubbonti® and Wyost® are first and only FDA-approved biosimilars to and interchangeable with Prolia*® and Xgeva*®Anticipated launch further strengthens Sandoz biosimilar portfolio and advances growth strategy
- Globe Newswire
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and qualitySandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolio Basel, April 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today an
